CagriSema vs Zepbound Guide
CagriSema vs Zepbound: the amylin combo versus the approved leader
Amylin + GLP-1
CagriSema's combo
~22% vs ~21%
REDEFINE vs SURMOUNT-1
Trials vs approved
the real difference
This is a comparison between a contender still in trials and a champion already on pharmacy shelves. CagriSema is Novo Nordisk's investigational combination of cagrilintide, a long-acting amylin analog, with semaglutide, the GLP-1 drug behind Wegovy and Ozempic. Its phase 3 REDEFINE program reported average weight loss around 22% in obesity. Zepbound is Lilly's approved tirzepatide, which reached roughly 21% in SURMOUNT-1. The numbers sit close together, which makes the honest point clear: CagriSema is a promising, unapproved combination, while Zepbound is a proven medicine you can be prescribed today. Availability, not a point or two of trial average, is what actually separates them right now.
Highlights
Key takeaways
- 01
CagriSema is investigational: cagrilintide (an amylin analog) plus semaglutide, from Novo Nordisk, not yet approved.
- 02
Zepbound is the approved tirzepatide (GLP-1/GIP dual agonist) from Eli Lilly, prescribable now.
- 03
CagriSema's phase 3 REDEFINE results landed around 22% average weight loss; Zepbound's SURMOUNT-1 reached about 21%.
- 04
CagriSema adds amylin biology to GLP-1, a different mechanism than tirzepatide's GLP-1/GIP combination.
- 05
The trial figures are close and come from different programs, so they do not crown a clear winner.
- 06
The decisive difference is availability: Zepbound can be prescribed today; CagriSema is trials-only.
CagriSema vs Zepbound at a glance
| Aspect | CagriSema | Zepbound |
|---|---|---|
| Status | Investigational (phase 3) | FDA-approved |
| Maker | Novo Nordisk | Eli Lilly |
| Mechanism | Amylin analog + GLP-1 | GLP-1 + GIP dual agonist |
| Reported weight loss | ~22% (REDEFINE) | ~21% (SURMOUNT-1) |
| Form | Weekly injection (in trials) | Weekly injection |
| Availability | Trials only | Prescribable now |
CagriSema figures are from its phase 3 program and may be refined; Zepbound figures are from its completed obesity trial. These are not a head-to-head comparison and are educational, not predictions.
What each one is
Zepbound is approved tirzepatide, the once-weekly GLP-1/GIP dual agonist that averages around 20% weight loss in obesity and is available by prescription. It is well characterized and backed by a completed phase 3 program.
CagriSema pairs semaglutide with cagrilintide, a long-acting analog of amylin, a second satiety hormone. It is Novo Nordisk's bid to push past semaglutide alone, and it is in late-stage trials, not approved. Every figure attached to it comes from the trial program.
Amylin combo vs dual agonist
The two take different routes to a similar destination. Zepbound combines GLP-1 with GIP, two incretin hormones. CagriSema combines GLP-1 (semaglutide) with amylin biology (cagrilintide), layering a different satiety pathway on top of the familiar one.
Neither mechanism is obviously superior on paper; both aim to deepen appetite suppression and metabolic effect beyond a single GLP-1 drug. The trial numbers, not the theory, are what will settle their relative place.
What the numbers show
CagriSema's REDEFINE phase 3 results reported average weight loss in the low-20s percent, in the same territory as Zepbound's roughly 21% in SURMOUNT-1. Early expectations for CagriSema had been even higher, and the readout, while strong, landed closer to the current leader than some had predicted.
As always, these are averages from separate trials in different populations, so the close numbers describe a tight field, not a decided contest.
Reading the close race honestly
When two drugs sit within a couple of points on trial averages, individual variation and adherence matter far more than the ranking. The best result comes from reaching a therapeutic dose, tolerating it, and staying on it, which favors whatever you can actually obtain and sustain.
Today that is Zepbound (and the other approved incretins). CagriSema may join them, but a strong phase 3 number is not a prescription.
Cautions worth carrying
Zepbound carries the class cautions (pancreatitis vigilance, gallbladder risk with rapid loss, the thyroid C-cell exclusion, reduced oral-contraceptive effectiveness) plus the standard GI effects during titration. CagriSema is expected to share the GLP-1 class cautions, with its full profile defined by the trial program and any eventual label.
And the market caution: CagriSema is not legitimately purchasable. Anything sold under the name is unregulated gray-market chemistry with no oversight.
Worth knowing before the headlines sweep you up
- CagriSema is investigational: no approval, no prescribing information yet
- Online CagriSema is unregulated gray-market chemistry with zero oversight
- The trial numbers are close; neither is a decided winner
- Zepbound is the proven, prescribable option in this comparison today
- Phase 3 figures can still be refined before any label
- Averages hide wide individual variation in both directions
What this means for you now
If you are choosing treatment today, Zepbound is the real option in this comparison, alongside the other approved incretins; the choice among them turns on coverage, tolerability, and your history.
If CagriSema eventually reaches the market, the preparation is unchanged: build the habits that make any of these drugs work on whatever you and your prescriber choose now. DoseLog carries them forward.
FAQ
Frequently asked questions
Is CagriSema better than Zepbound?
Their trial numbers are close: CagriSema's REDEFINE program reported roughly 22% average weight loss and Zepbound's SURMOUNT-1 about 21%, from separate trials. CagriSema is not approved, so Zepbound is the proven, prescribable option today.
What is the difference between CagriSema and Zepbound?
Mechanism and status. CagriSema combines semaglutide (GLP-1) with cagrilintide (an amylin analog) and is investigational. Zepbound is tirzepatide (GLP-1 plus GIP) and is FDA-approved. Same goal, different biology, different availability.
Can I get CagriSema now?
No. CagriSema is only available through clinical trials and has no approval or prescribing information. Anything sold as CagriSema online is unregulated and unsafe. Zepbound and the other approved incretins are the real options.
When will CagriSema be available?
Only after regulatory review of its phase 3 program; no approval exists yet and timelines are not guaranteed. Until then, approved options like Zepbound are what you can actually be prescribed.
Track your GLP-1 journey on one quiet line.
Log your shot, injection site, meals, and side-effect severity together, and walk into your next appointment with a week-by-week picture instead of a guess.
Sources
- 1.Novo Nordisk REDEFINE 1 and REDEFINE 2 phase 3 trials of CagriSema (cagrilintide + semaglutide): sponsor communications and conference presentations. Find on PubMed ↗
- 2.Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. SURMOUNT-1. NEJM 2022. Read on NEJM ↗
- 3.Published data on cagrilintide and the cagrilintide-semaglutide combination. Find on PubMed ↗
- 4.Zepbound (tirzepatide) prescribing information: dosing, adverse reactions, warnings. View label on DailyMed ↗
This guide is for general education and is not medical advice. It doesn't account for your personal medical history, other medications, or your individual situation, and it doesn't replace a conversation with your doctor or pharmacist. Do not start, stop, or change the dose of GLP-1 or any medication based on what you read here. If you think you have a medical emergency, call your local emergency number. DoseLog is a tracking app; drug and company names are used factually under nominative fair use, and DoseLog is not affiliated with, endorsed by, or sponsored by any manufacturer mentioned.
Keep reading
GLP-1 Comparison Matrix
Every GLP-1 medication compared: the full matrix
Wegovy vs Zepbound Guide
Wegovy vs Zepbound: the head-to-head, honestly read
Ozempic vs Mounjaro Guide
Ozempic vs Mounjaro: the diabetes head-to-head, honestly read
Ozempic vs Wegovy Guide
Ozempic vs Wegovy: the same drug, two labels, one honest answer